We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
Read MoreHide Full Article
AstraZeneca (AZN - Free Report) reported positive high-level results from multiple late-stage studies evaluating its blockbuster cancer drugs Tagrisso (osimertinib) and Imfinzi (durvalumab) in non-small cell lung cancer (NSCLC) indication.
The phase III ADAURA study evaluated Tagrisso as an adjuvant treatment for patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) NSCLC. Data from the study showed that treatment with Tagrisso led to statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo. Management did not report any safety concerns in study participants.
The ADAURA study had earlier achieved its primary endpoint of disease-free survival (DFS). Last year, management announced that treatment with Tagrisso demonstrated a median DFS of nearly 5.5 years.
Tagrisso is already approved for adjuvant early-stage EGFRm NSCLC based on data from the ADAURA study. Apart from this indication, the drug is already approved in two other NSCLC indications.
Tagrisso is also being evaluated by AstraZeneca in earlier stages of lung cancer, including in the neoadjuvant resectable setting, Stage IA2-IA3 adjuvant resectable setting and Stage III locally-advanced unresectable setting.
Shares of AstraZeneca have lost 5.5% in the year compared to the industry’s 8.8% decline.
Image Source: Zacks Investment Research
In a separate press release, AstraZeneca also announced positive interim data from the phase III AEGEAN study, which evaluated Imfinzi before and after surgery in patients with resectable early-stage (IIA-IIIB) NSCLC. Management announced that the study achieved the other primary endpoint of event-free survival (EFS), i.e., treatment with Imfinzi significantly increased the time patients live without recurrence or progression events.
Last year, management announced that the AEGEAN study achieved its primary endpoint of pathologic complete response (pCR) with statistical significance and meaningful improvement in the above patient group.
Imfinzi is already approved for multiple cancer indications. While the drug is already approved for two NSCLC indications, it is also approved in extensive-stage small cell lung cancer (ES-SCLC), biliary tract cancer (BTC) and hepatocellular carcinoma (uHCC) indications.
AstraZeneca is focused on strengthening its oncology business. In 2022, AZN generated $14.6 billion worth of total revenues from its Oncology business, reflecting a 19% year-over-year rise in the constant exchange rate, driven by a solid performance of newer medicines, such as Tagrisso, Lynparza, Imfinzi and Calquence. Management is working to further strengthen this portfolio through label expansions and advancing oncology pipeline candidates. AstraZeneca aims to develop a treatment for every form of cancer.
Estimates for Adaptive Biotechnologies’ 2023 loss per share have narrowed from $1.30 to $1.15 in the past 30 days. During the same period, the loss per share estimates for 2024 have narrowed from 99 cents to 94 cents. Shares of Adaptive Biotechnologies have risen 7.6% year-to-date.
Earnings of Adaptive Biotechnologies beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 10.75%. In the last reported quarter, ADPT delivered an earnings surprise of 24.32%.
In the past 30 days, estimates for CRISPR Therapeutics’ 2023 loss per share have narrowed from $8.21 to $7.39. Shares of CRISPR Therapeutics have risen 12.6% in the year-to-date period.
Earnings of CRISPR Therapeutics beat estimates in two of the last four quarters while missing the mark on the other two occasions, witnessing an earnings surprise of 3.19%, on average. In the last reported quarter, CRISPR Therapeutics’ earnings beat estimates by 39.22%.
In the past 30 days, estimates for Novo Nordisk’ 2023 earnings per share have risen from $4.20 to $4.43. During the same period, the earnings for 2024 have risen from $4.90 to $5.19. Shares of Novo Nordisk have risen 4.9% in the year-to-date period.
Earnings of Novo Nordisk beat estimates in three of the last four quarters while missing the mark on one occasion, witnessing an earnings surprise of 3.00%, on average. In the last reported quarter, Novo Nordisk’ earnings beat estimates by 2.47%.
Unique Zacks Analysis of Your Chosen Ticker
Pick one free report - opportunity may be withdrawn at any time
Image: Bigstock
AstraZeneca (AZN) Posts Positive Data From Lung Cancer Studies
AstraZeneca (AZN - Free Report) reported positive high-level results from multiple late-stage studies evaluating its blockbuster cancer drugs Tagrisso (osimertinib) and Imfinzi (durvalumab) in non-small cell lung cancer (NSCLC) indication.
The phase III ADAURA study evaluated Tagrisso as an adjuvant treatment for patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) NSCLC. Data from the study showed that treatment with Tagrisso led to statistically significant and clinically meaningful improvement in overall survival (OS), a key secondary endpoint, compared to placebo. Management did not report any safety concerns in study participants.
The ADAURA study had earlier achieved its primary endpoint of disease-free survival (DFS). Last year, management announced that treatment with Tagrisso demonstrated a median DFS of nearly 5.5 years.
Tagrisso is already approved for adjuvant early-stage EGFRm NSCLC based on data from the ADAURA study. Apart from this indication, the drug is already approved in two other NSCLC indications.
Tagrisso is also being evaluated by AstraZeneca in earlier stages of lung cancer, including in the neoadjuvant resectable setting, Stage IA2-IA3 adjuvant resectable setting and Stage III locally-advanced unresectable setting.
Shares of AstraZeneca have lost 5.5% in the year compared to the industry’s 8.8% decline.
Image Source: Zacks Investment Research
In a separate press release, AstraZeneca also announced positive interim data from the phase III AEGEAN study, which evaluated Imfinzi before and after surgery in patients with resectable early-stage (IIA-IIIB) NSCLC. Management announced that the study achieved the other primary endpoint of event-free survival (EFS), i.e., treatment with Imfinzi significantly increased the time patients live without recurrence or progression events.
Last year, management announced that the AEGEAN study achieved its primary endpoint of pathologic complete response (pCR) with statistical significance and meaningful improvement in the above patient group.
Imfinzi is already approved for multiple cancer indications. While the drug is already approved for two NSCLC indications, it is also approved in extensive-stage small cell lung cancer (ES-SCLC), biliary tract cancer (BTC) and hepatocellular carcinoma (uHCC) indications.
AstraZeneca is focused on strengthening its oncology business. In 2022, AZN generated $14.6 billion worth of total revenues from its Oncology business, reflecting a 19% year-over-year rise in the constant exchange rate, driven by a solid performance of newer medicines, such as Tagrisso, Lynparza, Imfinzi and Calquence. Management is working to further strengthen this portfolio through label expansions and advancing oncology pipeline candidates. AstraZeneca aims to develop a treatment for every form of cancer.
AstraZeneca PLC Price
AstraZeneca PLC price | AstraZeneca PLC Quote
Zacks Rank & Stocks to Consider
AstraZeneca currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the overall healthcare sector include Adaptive Biotechnologies Corporation (ADPT - Free Report) , CRISPR Therapeutics (ADCT - Free Report) andNovo Nordisk (NVO - Free Report) . While Novo Nordisk sports a Zacks Rank #1 (Strong Buy), Adaptive Biotechnologies and CRISPR Therapeutics carry a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Estimates for Adaptive Biotechnologies’ 2023 loss per share have narrowed from $1.30 to $1.15 in the past 30 days. During the same period, the loss per share estimates for 2024 have narrowed from 99 cents to 94 cents. Shares of Adaptive Biotechnologies have risen 7.6% year-to-date.
Earnings of Adaptive Biotechnologies beat estimates in three of the last four quarters and missed the mark on one occasion, the average surprise being 10.75%. In the last reported quarter, ADPT delivered an earnings surprise of 24.32%.
In the past 30 days, estimates for CRISPR Therapeutics’ 2023 loss per share have narrowed from $8.21 to $7.39. Shares of CRISPR Therapeutics have risen 12.6% in the year-to-date period.
Earnings of CRISPR Therapeutics beat estimates in two of the last four quarters while missing the mark on the other two occasions, witnessing an earnings surprise of 3.19%, on average. In the last reported quarter, CRISPR Therapeutics’ earnings beat estimates by 39.22%.
In the past 30 days, estimates for Novo Nordisk’ 2023 earnings per share have risen from $4.20 to $4.43. During the same period, the earnings for 2024 have risen from $4.90 to $5.19. Shares of Novo Nordisk have risen 4.9% in the year-to-date period.
Earnings of Novo Nordisk beat estimates in three of the last four quarters while missing the mark on one occasion, witnessing an earnings surprise of 3.00%, on average. In the last reported quarter, Novo Nordisk’ earnings beat estimates by 2.47%.